AUPH
What one share of Aurinia Pharmaceuticals holds
Pharmaceutical Preparations
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”).
Aurinia Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.28 |
|---|---|
| Profit | $2.30 |
| Cash and investments | $1.35 |
| Book value | $4.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$0.63 | — | −$0.61 | — | $1.59 |
| 2019 | — | −$0.95 | — | −$0.68 | — | $2.67 |
| 2020 | $0.42 | −$0.87 | — | −$0.59 | — | $3.22 |
| 2021 | $0.35 | −$1.40 | — | −$1.22 | — | $3.38 |
| 2022 | $0.94 | −$0.76 | — | −$0.56 | — | $2.85 |
| 2023 | $1.23 | −$0.54 | — | −$0.23 | — | $2.63 |
| 2024 | $1.61 | $0.04 | — | $0.30 | — | $2.68 |
| 2025 | $2.04 | $2.07 | — | $0.98 | — | $4.39 |